勘误：吡咯替尼治疗HER2阳性转移性乳腺癌患者的有效性、安全性及生物标志物与无进展生存期的关系：一项真实世界、多中心分析
Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.
作者信息
Chen Qitong, Ouyang Dengjie, Anwar Munawar, Xie Ning, Wang Shouman, Fan Peizhi, Qian Liyuan, Chen Gannong, Zhou Enxiang, Guo Lei, Gu Xiaowen, Ding Boni, Yang Xiaohong, Liu Liping, Deng Chao, Xiao Zhi, Li Jing, Wang Yunqi, Zeng Shan, Hu Jinhui, Zhou Wei, Qiu Bo, Wang Zhongming, Weng Jie, Liu Mingwen, Li Yi, Tang Tiegang, Wang Jianguo, Zhang Hui, Dai Bin, Tang Wuping, Wu Tao, Xiao Maoliang, Li Xiantao, Liu Hailong, Li Lai, Yi Wenjun, Ouyang Quchang
机构信息
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Department of General Surgery, Xiangya Hospital Central South University, Changsha, China.
出版信息
Front Oncol. 2021 Mar 5;11:661128. doi: 10.3389/fonc.2021.661128. eCollection 2021.
Abstract
[This corrects the article DOI: 10.3389/fonc.2020.00811.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fonc.2020.00811。]
相似文献
1
Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.勘误：吡咯替尼治疗HER2阳性转移性乳腺癌患者的有效性、安全性及生物标志物与无进展生存期的关系：一项真实世界、多中心分析
Front Oncol. 2021 Mar 5;11:661128. doi: 10.3389/fonc.2021.661128. eCollection 2021.
2
Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.吡咯替尼治疗HER2阳性转移性乳腺癌患者的有效性、安全性及生物标志物与无进展生存期的关系：一项真实世界、多中心分析
Front Oncol. 2020 May 25;10:811. doi: 10.3389/fonc.2020.00811. eCollection 2020.
3
[Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].吡咯替尼口服治疗HER2阳性转移性乳腺癌的疗效与安全性：真实世界实践
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Apr 18;52(2):254-260. doi: 10.19723/j.issn.1671-167X.2020.02.010.
4
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌（PHOEBE）：一项多中心、开放标签、随机、对照、Ⅲ期临床试验。
Lancet Oncol. 2021 Mar;22(3):351-360. doi: 10.1016/S1470-2045(20)30702-6. Epub 2021 Feb 11.
5
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.吡咯替尼联合曲妥珠单抗和芳香化酶抑制剂作为一线治疗方案用于治疗人表皮生长因子受体 2（HER2）阳性且激素受体阳性的转移性或局部晚期乳腺癌：一项随机对照试验的研究方案。
BMC Cancer. 2020 Jul 13;20(1):653. doi: 10.1186/s12885-020-07143-2.
6
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.吡咯替尼的 I 期研究和生物标志物分析，一种新型不可逆的泛-ErbB 受体酪氨酸激酶抑制剂，用于治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者。
J Clin Oncol. 2017 Sep 20;35(27):3105-3112. doi: 10.1200/JCO.2016.69.6179. Epub 2017 May 12.
7
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.吡咯替尼或拉帕替尼联合卡培他滨治疗既往接受紫杉类、蒽环类和/或曲妥珠单抗治疗的 HER2 阳性转移性乳腺癌：一项随机、Ⅱ期研究。
J Clin Oncol. 2019 Oct 10;37(29):2610-2619. doi: 10.1200/JCO.19.00108. Epub 2019 Aug 20.
8
Metastatic brain tumors respond favorably to pyrotinib in a HER2-positive breast cancer following failure using trastuzumab.在使用曲妥珠单抗治疗失败后的HER2阳性乳腺癌中，转移性脑肿瘤对吡咯替尼反应良好。
Am J Transl Res. 2020 Sep 15;12(9):5874-5881. eCollection 2020.
9
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.吡咯替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者的安全性、有效性和生物标志物分析：一项 I 期临床试验。
Clin Cancer Res. 2019 Sep 1;25(17):5212-5220. doi: 10.1158/1078-0432.CCR-18-4173. Epub 2019 May 28.
10
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.非小细胞肺癌中的 HER2 外显子 20 插入对不可逆的泛 HER 受体酪氨酸激酶抑制剂吡咯替尼敏感。
Ann Oncol. 2019 Mar 1;30(3):447-455. doi: 10.1093/annonc/mdy542.
Zotero 插件